[HTML][HTML] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

JT Brandt, SL Close, SJ Iturria, CD Payne… - Journal of Thrombosis …, 2007 - Elsevier
Background: Thienopyridines are metabolized to active metabolites that irreversibly inhibit
the platelet P2Y 12 adenosine diphosphate receptor. The pharmacodynamic response to …

Cytochrome 2C19* 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

D Sibbing, W Koch, D Gebhard, T Schuster, S Braun… - Circulation, 2010 - Am Heart Assoc
Background—The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in
clopidogrel metabolization. A recently explored CYP2C19* 17 allelic variant has been linked …

CYP2C19* 2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention

G Kassimis, P Davlouros, I Xanthopoulou… - Thrombosis research, 2012 - Elsevier
INTRODUCTION: Information regarding any possible additional effect of genetic variants
other than CYP2C19* 2 on platelet reactivity in patients undergoing percutaneous coronary …

Genotyping: one piece of the puzzle to personalize antiplatelet therapy

PA Gurbel, US Tantry, AR Shuldiner… - Journal of the American …, 2010 - jacc.org
The loss-of-function hepatic cytochrome P450 (CYP) 2C19* 2 allele has been associated
with reduced clopidogrel active metabolite generation and higher ex vivo platelet reactivity …

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

DJ Angiolillo, A Fernandez-Ortiz… - … , and vascular biology, 2006 - Am Heart Assoc
Objectives—Metabolic activity of cytochrome P450 (CYP) 3A4 has been associated with
clopidogrel response variability. Because metabolic activity of CYP3A4 is genetically …

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

K Umemura, T Furuta, K Kondo - Journal of Thrombosis and …, 2008 - jthjournal.org
Clopidogrel is a thienopyridine derivative with ADP-antagonistic activity and is widely used
for the prevention of ischemic events in patients who have suffered a stroke, non-ST …

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

T Geisler, E Schaeffeler, J Dippon, S Winter… - …, 2008 - Taylor & Francis
Aims: To investigate an association of responsiveness to clopidogrel loading dose with
genotypes of cytochrome P450 (CYP) 2C19, other CYP isozymes and nongenetic factors in …

Protective effect of the CYP2C19* 17 polymorphism with increased activation of clopidogrel on cardiovascular events

KA Tiroch, D Sibbing, W Koch, T Roosen-Runge… - American heart …, 2010 - Elsevier
BACKGROUND: The prodrug clopidogrel requires activation by cytochrome P-450 (CYP)
enzymes for its antiplatelet effect. The genes encoding enzymes for clopidogrel activation …

Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction

S Cresci, JP Depta, PA Lenzini, AY Li… - Circulation …, 2014 - Am Heart Assoc
Background—Clopidogrel is recommended after acute myocardial infarction but has
variable efficacy and safety, in part related to the effect of cytochrome P450 (CYP) …

The cytochrome 2C19* 2 and* 3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention

SJ Hwang, YH Jeong, IS Kim, JS Koh, MK Kang… - Thrombosis research, 2011 - Elsevier
INTRODUCTION: Carriage of CYP2C19* 2 allele is associated with diminished platelet
response to clopidogrel. However, the loss-of-function impact of CYP2C19* 3 allele on …